Royalty Pharma plc Class A Ordinary Shares

Day range

$64.06 – $65.35

Open

$64.14

Prev close

$63.86

Volume

1.65M

Market cap

$28.44B

Shares out

445.28M

P/E

34.89

P/S

11.21

P/B

4.16

P/FCF

9.55

ROE

11.9%

ROA

4.1%

Debt/Equity

1.33

Div yield

1.40%

As of Oct 23, 2026

• Annual meeting resultsJun 4, 2026

  On June 4, 2026, Royalty Pharma plc (the "Company") held its 2026 Annual General Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on 10 proposals... The Company's inspector of election certified the following vote tabulations.

• Debt retirementMay 28, 2026

  The Credit Agreement refinanced and replaced in its entirety that certain Revolving Credit Agreement, dated as of September 15, 2021, among the Company as Borrower, RPH, the Administrative Agent and the lenders thereto (as amended, restated, amended and restated, supplemented or otherwise modified, the "Existing Credit Agreement"), and at effectiveness of the Credit Agreement, all obligations outstanding under the Existing Credit Agreement were repaid and all commitments under the Existing Credit Agreement were terminated in full.

• Credit facilityApr 13, 2026

  Royalty Pharma is providing a senior secured term loan of up to $750 million in three tranches, and the first $250 million tranche must be drawn following FDA approval of daraxonrasib for metastatic PDAC. The two additional $250 million tranches are available at Revolution Medicines' option based on the achievement of certain trailing four-quarter net sales milestones for daraxonrasib.

• Regulatory decisionDec 22, 2025

  On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration approved a New Drug Application for MYQORZO (aficamten). MYQORZO is a cardiac myosin inhibitor for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

• Executive officer appointmentDec 22, 2025

  Arthur R. McGivern, age 50, Executive Vice President and General Counsel of the Company, will assume Mr. Lloyd's responsibilities effective January 1, 2026. Mr. McGivern joined the Company in October 2022. Previously, Mr. McGivern was a partner at Goodwin Procter LLP.

Days to cover

4.4

Short interest

12.89M

Avg volume

2.9M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
  positiveThe Motley Fool· Oct 25, 2026
• Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
  neutralZacks Investment Research· Oct 13, 2026
• Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
  positiveZacks Investment Research· Oct 8, 2026
• Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
  positiveThe Motley Fool· Oct 1, 2026
• Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
  positiveThe Motley Fool· Sep 11, 2026